Precigen (NASDAQ:PGEN) Insider Sells $127,011.16 in Stock

Precigen, Inc. (NASDAQ:PGEN) insider Donald Lehr sold 29,131 shares of Precigen stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total transaction of $127,011.16. Following the sale, the insider owned 755,461 shares in the company, valued at approximately $3,293,809.96. This represents a 3.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Precigen Stock Down 1.3%

NASDAQ:PGEN opened at $3.81 on Thursday. The firm’s 50 day simple moving average is $4.06 and its 200 day simple moving average is $4.09. The company has a debt-to-equity ratio of 4.62, a current ratio of 4.82 and a quick ratio of 4.12. Precigen, Inc. has a one year low of $1.30 and a one year high of $5.47. The company has a market cap of $1.36 billion, a PE ratio of -3.23 and a beta of 1.06.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $23.25 million for the quarter, compared to the consensus estimate of $20.81 million. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. On average, research analysts anticipate that Precigen, Inc. will post -0.02 earnings per share for the current year.

Analysts Set New Price Targets

PGEN has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Precigen from a “buy” rating to a “hold” rating in a research report on Sunday. HC Wainwright boosted their price target on shares of Precigen from $11.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a research report on Tuesday, April 21st. Citizens Jmp boosted their price target on shares of Precigen from $9.00 to $11.00 and gave the stock a “market outperform” rating in a research report on Thursday, May 14th. Finally, Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $12.50.

Institutional Trading of Precigen

Several hedge funds have recently modified their holdings of the stock. Xponance LLC increased its stake in shares of Precigen by 21.3% in the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 2,496 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock valued at $170,000 after acquiring an additional 2,993 shares in the last quarter. Composition Wealth LLC increased its stake in shares of Precigen by 16.5% in the 4th quarter. Composition Wealth LLC now owns 21,217 shares of the biotechnology company’s stock valued at $89,000 after acquiring an additional 3,000 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 3,137 shares in the last quarter. Finally, Strs Ohio increased its stake in shares of Precigen by 6.8% in the 3rd quarter. Strs Ohio now owns 50,400 shares of the biotechnology company’s stock valued at $166,000 after acquiring an additional 3,200 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.